European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

RegulatorydaraxonrasibPositive

AI Analysis

Summary

Revolution Medicines announced that the EMA's CHMP has initiated a phased review of daraxonrasib, its RAS(ON) inhibitor for pancreatic cancer, which has been designated as an orphan medicinal product and recognized as high priority under the EMA's Cancer Medicines Pathfinder project to accelerate assessment.

Outcome Details

EMA CHMP initiated phased review of daraxonrasib; designated as orphan medicinal product and recognized as high priority under Cancer Medicines Pathfinder project

Importance:7/10

Sentiment:

0.70

EMAregulatory approvalphased revieworphan designationoncologyRAS inhibitorpancreatic canceraccelerated review

Related Companies

$RVMD

Read the original article

Published by GlobeNewswire Clinical Studies on July 7, 2026 1:23 PM

Read Original